NASDAQ:GPCR Structure Therapeutics Q3 2026 Earnings Date & Estimates $25.67 -1.01 (-3.79%) Closing price 10/8/2026 04:00 PM EasternExtended Trading$25.50 -0.17 (-0.67%) As of 04:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Structure Therapeutics is expected to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeBefore Market OpensConference Call DateNovember 6, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Structure Therapeutics in Q3 2026Structure Therapeutics is expected to post earnings of -$0.33 per share on revenue of $50.00 million. In the same quarter a year earlier Structure Therapeutics reported -$0.37 per share. Structure Therapeutics last reported on August 6, 2026, posting -$0.49 per share and missing the -$0.39 consensus estimate. Structure Therapeutics has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.33Expected Revenue$50.00 millionPrior-Year EPS-$0.37Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.49 (Missed by -$0.10)EPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Structure Therapeutics Q3 2026 Earnings FAQ When does Structure Therapeutics report Q3 2026 earnings? Structure Therapeutics (NASDAQ:GPCR) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Structure Therapeutics' Q3 2026 earnings call? Structure Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Structure Therapeutics? Analysts expect Structure Therapeutics to post earnings of -$0.33 per share for Q3 2026. How much revenue is Structure Therapeutics expected to report? The consensus revenue estimate for Structure Therapeutics is $50.00 million for Q3 2026. Structure Therapeutics Earnings HeadlinesStructure Therapeutics (NASDAQ:GPCR) Stock Rating Cut to Strong Sell at Wall Street ZenOctober 3, 2026 | americanbankingnews.comGPCR Share News TodaySeptember 24, 2026 | uk.investing.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow. | Base Camp Trading (Ad)Structure Therapeutics (GPCR) Gains Fresh Obesity Trial Backing Following Data That Keeps Valuation In FocusSeptember 22, 2026 | finance.yahoo.comStructure Therapeutics Inc ADR (GPCR)September 19, 2026 | za.investing.comStructure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comSee More Structure Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Structure Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Structure Therapeutics and other key companies, straight to your email. Email Address About Structure TherapeuticsStructure Therapeutics (NASDAQ:GPCR) Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic and cardiopulmonary diseases. The company uses structure-based drug discovery and related technologies to identify therapies intended to address conditions with significant unmet medical needs. Its lead product candidate is GSBR-1290, an investigational oral small-molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor being developed for obesity and type 2 diabetes. Unlike injectable GLP-1 therapies, the candidate is designed as an oral treatment. Structure Therapeutics is also advancing additional discovery and development programs targeting metabolic, cardiovascular and pulmonary diseases. Structure Therapeutics operates internationally, with activities and personnel in the United States and China. The company was formerly known as Shouyao Holdings and became a publicly traded company on the Nasdaq under the symbol GPCR in 2023. Its scientific and executive leadership includes experienced drug-discovery and biotechnology professionals, supported by a team focused on translating structural biology into potential medicines.View Structure Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
